This modulation of inflammatory signaling occurs through activation of the PI3K/AKT pathway, which possesses intrinsic anti-inflammatory properties including inhibition of pro-inflammatory cytokine release and enhancement of cellular stress resistance
Peptides: Peptides like BPC-157, KPV, and Thymosin Alpha-1 are generally very well-tolerated
This selective targeting ensures that Cis-Pt is released specifically at the tumor site, enhancing the cytotoxic effect on GBM cells while minimizing systemic side effects
5c and Supplementary Figs
7583% achieved 15% 26% of participants on 12 mg achieved 30% weight reduction Cardiometabolic Parameters Improvements in blood pressure, HbA1c, fasting glucose, insulin, LDL-cholesterol 72% of patients with prediabetes achieved normoglycemia Safety Most common adverse events: gastrointestinal (nausea, diarrhea, constipation) , dose-dependent, predominantly mild to moderate Heart rate: slight increase up to week 24, then decrease No severe hypoglycemia, medullary carcinoma, or C-cell hyperplasia Conclusions Retatrutide induced significant, dose-dependent weight reduction of up to 24.2% over 48 weeks
